234 related articles for article (PubMed ID: 9422062)
1. [New molecular target of cancer therapy--angiogenesis regulator VEGF].
Toi M; Ueno T; Tominaga T
Gan To Kagaku Ryoho; 1997 Dec; 24(15):2202-6. PubMed ID: 9422062
[TBL] [Abstract][Full Text] [Related]
2. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
4. Measuring VEGF-Flk-1 activity and consequences of VEGF-Flk-1 targeting in vivo using intravital microscopy: clinical applications.
Vajkoczy P; Thurnher A; Hirth KP; Schilling L; Schmiedek P; Ullrich A; Menger MD
Oncologist; 2000; 5 Suppl 1():16-9. PubMed ID: 10804086
[TBL] [Abstract][Full Text] [Related]
5. Anticancer therapy with angiogenesis inhibitors.
Ghilardi C; Bani MR; Giavazzi R
Tumori; 2001; 87(6):S14-6. PubMed ID: 11989610
[No Abstract] [Full Text] [Related]
6. [Advances in the study of the role of vascular endothelial growth factor and its receptor in tumor angiogenesis and its relation with anti-angiogenesis effect].
Bian X; Shi J
Zhonghua Bing Li Xue Za Zhi; 1997 Aug; 26(4):248-50. PubMed ID: 10072871
[No Abstract] [Full Text] [Related]
7. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of vascular endothelial growth factor (VEGF) receptor 2 (KDR/Flk-1) activity by a monoclonal anti-VEGF antibody blocks tumor growth in mice.
Brekken RA; Overholser JP; Stastny VA; Waltenberger J; Minna JD; Thorpe PE
Cancer Res; 2000 Sep; 60(18):5117-24. PubMed ID: 11016638
[TBL] [Abstract][Full Text] [Related]
9. VEGF receptor signaling in tumor angiogenesis.
McMahon G
Oncologist; 2000; 5 Suppl 1():3-10. PubMed ID: 10804084
[TBL] [Abstract][Full Text] [Related]
10. Advances in the use of angiogenesis inhibitors in cancer.
Pinedo HM
Cancer J; 2001; 7 Suppl 3():S107-8. PubMed ID: 11779080
[No Abstract] [Full Text] [Related]
11. Solution structure of a phage-derived peptide antagonist in complex with vascular endothelial growth factor.
Pan B; Li B; Russell SJ; Tom JY; Cochran AG; Fairbrother WJ
J Mol Biol; 2002 Feb; 316(3):769-87. PubMed ID: 11866530
[TBL] [Abstract][Full Text] [Related]
12. Treatment for malignant pleural effusion of human lung adenocarcinoma by inhibition of vascular endothelial growth factor receptor tyrosine kinase phosphorylation.
Yano S; Herbst RS; Shinohara H; Knighton B; Bucana CD; Killion JJ; Wood J; Fidler IJ
Clin Cancer Res; 2000 Mar; 6(3):957-65. PubMed ID: 10741721
[TBL] [Abstract][Full Text] [Related]
13. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM
Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor in breast cancer: biologic and therapeutic aspects.
Sledge GW
Semin Oncol; 2002 Jun; 29(3 Suppl 11):104-10. PubMed ID: 12138404
[TBL] [Abstract][Full Text] [Related]
15. VEGF antagonists.
Hasan J; Jayson GC
Expert Opin Biol Ther; 2001 Jul; 1(4):703-18. PubMed ID: 11727506
[TBL] [Abstract][Full Text] [Related]
16. Importance of platelets in VEGF-mediated angiogenesis in tumors.
Salgado R; Benoy I; Dirix L; Vermeulen P; Van Marck E
FEBS Lett; 2002 Jun; 520(1-3):182. PubMed ID: 12044894
[No Abstract] [Full Text] [Related]
17. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
18. Angiogenesis research enjoys growth spurt in the 1990s.
Ziegler J
J Natl Cancer Inst; 1996 Jun; 88(12):786-8. PubMed ID: 8637041
[No Abstract] [Full Text] [Related]
19. VEGF in brain tumors.
Machein MR; Plate KH
J Neurooncol; 2000; 50(1-2):109-20. PubMed ID: 11245271
[TBL] [Abstract][Full Text] [Related]
20. The pivotal role of VEGF in tumor angiogenesis: molecular facts and therapeutic opportunities.
Siemeister G; Martiny-Baron G; Marmé D
Cancer Metastasis Rev; 1998 Jun; 17(2):241-8. PubMed ID: 9770121
[No Abstract] [Full Text] [Related]
[Next] [New Search]